About Akari Therapeutics PLC
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.akaritx.com/
Frequently Asked Questions
What is the 52-week range for AKTX?
The 52-week high is $44.2 and the 52-week low is $3.015.
What is the P/E ratio for AKTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for AKTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -147.45%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.31.
Analyst Recommendation Trends
Wall Street analyst consensus for AKTX over the last few months:
Latest AKTX News
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform TAMPA, Fla. and LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955,
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earnings
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | Gaslightwala Abizer | +6,430 | $9.72 | $62,500 |
| 2026-08-17 | Farag Kameel D. | +1,728 | $7.52 | $12,995 |
| 2026-07-16 | Farag Kameel D. | +1,130 | $11.5 | $12,995 |
| 2026-07-07 | Patel Samir Rashmikant | +5,799 | $16.16 | $93,712 |
| 2026-07-07 | Patel Samir Rashmikant | +15,466 | $16.16 | $249,931 |
| 2026-07-07 | Patel Samir Rashmikant | +1,209 | $32 | $38,688 |
| 2026-07-07 | Patel Samir Rashmikant | +5,799 | $0.0004 | $2 |
| 2026-07-07 | Patel Samir Rashmikant | +15,466 | $0.0004 | $6 |
| 2026-07-07 | Patel Samir Rashmikant | +1,209 | $8 | $9,672 |
| 2026-06-24 | Farag Kameel D. | +1,000 | $13 | $13,000 |
| 2026-06-24 | Farag Kameel D. | +7,353 | $3.74 | $27,500 |
| 2026-06-24 | Farag Kameel D. | +3,725 | $3.49 | $13,000 |
| 2026-06-24 | Farag Kameel D. | +2,539 | $5.12 | $13,000 |
| 2026-06-24 | Farag Kameel D. | +1,570 | $8.28 | $13,000 |
| 2026-06-24 | Farag Kameel D. | +1,395 | $9.32 | $13,001 |
| 2026-06-24 | Farag Kameel D. | +1,248 | $10.02 | $12,505 |
| 2026-06-24 | Gaslightwala Abizer | +15,563 | - | - |
| 2026-06-24 | Gaslightwala Abizer | +5,500 | - | - |
| 2025-12-16 | Neal James R | +3,093 | $0.4041 | $1,250 |
| 2025-12-16 | Neal James R | +3,093 | - | - |
| 2025-12-16 | Neal James R | +2,473 | $0.4041 | $999 |
| 2025-12-16 | Neal James R | +2,473 | - | - |
| 2025-12-16 | Prudo-Chlebosz Raymond | +386,661 | $0.4041 | $156,250 |
| 2025-12-16 | Prudo-Chlebosz Raymond | +386,661 | - | - |
| 2025-12-16 | Prudo-Chlebosz Raymond | +618,658 | $0.4041 | $250,000 |
| 2025-12-16 | Prudo-Chlebosz Raymond | +618,658 | - | - |
| 2025-12-16 | Patel Sandip I | +154,664 | $0.4041 | $62,500 |
| 2025-12-16 | Patel Sandip I | +154,664 | - | - |
| 2025-12-16 | Patel Sandip I | +247,462 | $0.4041 | $99,999 |
| 2025-12-16 | Patel Sandip I | +247,462 | - | - |
| 2025-12-16 | Farag Kameel D. | +24,745 | $0.4041 | $9,999 |
| 2025-12-16 | Farag Kameel D. | +24,745 | - | - |
| 2025-12-16 | Patel Samir Rashmikant | +231,997 | $0.4041 | $93,750 |
| 2025-12-16 | Patel Samir Rashmikant | +231,997 | - | - |
| 2025-12-16 | Patel Samir Rashmikant | +618,658 | $0.4041 | $250,000 |
| 2025-12-16 | Patel Samir Rashmikant | +618,658 | - | - |
| 2025-12-16 | Gaslightwala Abizer | +773,323 | $0.4041 | $312,500 |
| 2025-12-16 | Gaslightwala Abizer | +773,323 | - | - |
| 2025-12-16 | Gaslightwala Abizer | +309,328 | $0.4041 | $124,999 |
| 2025-12-16 | Gaslightwala Abizer | +309,328 | - | - |
| 2025-12-16 | Bazemore Robert B | +30,932 | $0.4041 | $12,500 |
| 2025-12-16 | Bazemore Robert B | +30,932 | - | - |
| 2025-12-16 | Bazemore Robert B | +123,731 | $0.4041 | $50,000 |
| 2025-12-16 | Bazemore Robert B | +123,731 | - | - |
| 2025-12-16 | Huh Hoyoung | +3,093,293 | $0.4041 | $1,250,000 |
| 2025-12-16 | Huh Hoyoung | +3,093,293 | - | - |
| 2025-12-16 | Huh Hoyoung | +618,658 | $0.4041 | $250,000 |
| 2025-12-16 | Huh Hoyoung | +618,658 | - | - |
| 2025-11-01 | Farag Kameel D. | +26,619 | $0.75 | $19,964 |
| 2025-11-01 | Farag Kameel D. | +32,000 | $0.75 | $24,000 |
| 2025-10-22 | Farag Kameel D. | +6,277 | $0.74 | $4,645 |